Systematic evaluation of clinical trial protocols of new drugs as a cure of chronic hepatitis B
10.3760/cma.j.cn501113-20200609-00305-1
- VernacularTitle:治愈慢性乙型肝炎新药临床试验方案的系统评价
- Author:
Sha CHEN
1
;
Lianhui ZHAO
;
Shan SHAN
;
Min LI
;
Yameng SUN
;
Jialing ZHOU
;
Xiaoning WU
;
Ruihua DONG
;
Yuanyuan KONG
;
Xiaojuan OU
;
Hong MA
;
Hong YOU
;
Jidong JIA
Author Information
1. 首都医科大学附属北京友谊医院肝病中心 肝硬化转化医学北京市重点实验室 国家消化系统疾病临床医学研究中心 100050
- Keywords:
Hepatitis B, chronic;
Cure;
Clinical trials;
Systematic review
- From:
Chinese Journal of Hepatology
2020;28(8):662-666
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To describe the current status of registration and design characteristics of clinical trials of new drugs for curing hepatitis B through domestic and foreign websites, so as to provide references for the follow-up clinical trials of new hepatitis B drugs.Methods:A search was conducted on the US Clinical Trials Database and the Chinese Clinical Trial Registry Center. The search date was from the establishment of the database to May 26, 2020, and the registration trials of new drugs for curing hepatitis B at home and abroad were included. Two researchers independently searched and screened the literature and extracted the data.Results:A total of 106 registered clinical trials of new drugs for curing hepatitis B were included (94 English registration websites and 12 Chinese registration websites), and the number of registrations had increased year by year. Among them, the proportion of therapeutic vaccines and core protein inhibitors were the highest, accounting for 27.4% ( n = 29) and 22.6% ( n = 24), respectively. The vast majority of clinical trials ( n = 96, 90.6%) were in the early stages (Phase I and II). The subjects in phase I clinical trial were mainly healthy people and treated CHB patients, while the subjects in phase II clinical trial were mainly CHB patients who had achieved viral suppression after initial or post-treatment. The main evaluation indicators of Phase I clinical trials were the safety and tolerability of new drugs. The main evaluation indicators in about half of Phase II clinical trials were HBsAg negative conversion/quantitative decline. Overall, the number of clinical trials with the new design was small, accounting for 3.8% (4 / 106). There were relatively few trials of new drugs for curing hepatitis B on domestic registration websites, and the information provided was incomplete. Conclusion:The number of clinical trials of new hepatitis B drugs at home and abroad is increasing year by year, but most of them are in phase I and II, with few adopting new designs. In addition, the information integrity of the domestic website registration center needs to be improved.
